Mersana Therapeutics, Inc. CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and ...
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
This page features the latest news about the Mersana Therapeutics stock. MRSN stock touches 52-week low at $0.56 amid market challenges Mersana Therapeutics Inc . (NASDAQ:MRSN) stock has reached a ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mersana Therapeutics (MRSN – Research Report) and Natera (NTRA – Research Report) with bullish ...
Bala Mohan, the Senior Vice President and Chief Development Officer at Mersana Therapeutics, Inc. (NASDAQ:MRSN), recently sold shares of the company as per a filing with the Securities and ...
Hosted on MSN29d
Mersana therapeutics VP Mandelia sells $1,128 in stockCAMBRIDGE, MA—Mersana Therapeutics, Inc. (NASDAQ:MRSN) recently reported that Ashish Mandelia, the company's Vice President and Chief Accounting Officer, executed a sale of common stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback